Arbitration & Dispute Resolution

• Representing the founder of a China-based healthcare company in an HKIAC-administered arbitration under the HKIAC Administered Arbitration Rules, relating to a US$100 million credit facility dispute
• Representing a Chinese conglomerate in an HKIAC-administered arbitration under the UNCITRAL Arbitration Rules, relating to a shareholder dispute over corporate governance rights
• Representing a China-based biomed company in an HKIAC-administered arbitration under the UNCITRAL Arbitration Rules, relating to a minority shareholder redemption claim
• Representing U.S. private equity investors in an ICC-administered arbitration, relating to a joint venture dispute
• Advising a European telecom company on a US$200 million indemnity claim in an LCIA-administered arbitration
• Advising a China-based biotech company on a post-acquisition dispute relating to earn-out consideration exceeding US$100 million
• Advising a China-based biotech company on breach of fiduciary duty claims against a former director involving various jurisdictions
• Advising a China-based biotech company on post-M&A litigation indemnity claims
• Advising a Chinese entrepreneur on shareholder disputes exceeding US$180 million across four common law jurisdictions

Regulatory Investigations & Enforcement

• Advising the former CEO of a U.S.-listed technology company in a U.S. Securities and Exchange Commission investigation in relation to insider dealing
• Advising various Hong Kong-listed companies in investigations conducted by the Hong Kong Stock Exchange and/or the Hong Kong Securities and Futures Commission
• Advising various international investment banks in investigations conducted by the Hong Kong Stock Exchange, Hong Kong Securities and Futures Commission and/or the Hong Kong Monetary Authority
• Advising accounting firms in investigations conducted by the Hong Kong Accounting and Financial Reporting Council
• Advising global technology companies on U.S. regulatory investigations concerning alleged FCPA violations in the procurement, marketing, and sales practices in China
• Conducting internal investigations for a multinational pharmaceutical company in relation to alleged FCPA violations in the Asia-Pacific region
• Conducting internal investigations for a Chinese-foreign joint venture investment bank in relation to employee misconduct